Kristen Albright is the CEO of Prokarium, a privately held biotech developing living cures. She joined Prokarium in 2018, most recently serving as Chief Operating Officer, and has led Prokarium’s expanding development efforts in oncology, successfully closing their latest $30M financing round in 2023 and entering into a large R&D partnership with Ginkgo Bioworks. Prior to Prokarium, Kristen was an investor at Osage University Partners, where she led several early-stage investments into life sciences companies. Earlier in her career, she worked within business development and M&A at Emergent BioSolutions and Cangene Corporation. Kristen started her industry career as a post-doctoral fellow at Centocor and earned her Doctor of Pharmacy from the Philadelphia College of Pharmacy and MBA from Saint Joseph’s University.